PMID- 19041000
OWN - NLM
STAT- MEDLINE
DCOM- 20081212
LR  - 20151119
IS  - 1532-7361 (Electronic)
IS  - 0039-6060 (Linking)
VI  - 144
IP  - 6
DP  - 2008 Dec
TI  - The potential clinical relevance of serum vascular endothelial growth factor 
      (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma.
PG  - 934-40; discussion 940-1
LID - 10.1016/j.surg.2008.07.027 [doi]
AB  - BACKGROUND: Vascular endothelial growth factor (VEGF) promotes tumor 
      angioinvasion while VEGF-C is a potent lymphangiogenic factor. This study aims at 
      evaluating serum VEGF (sVEGF) and sVEGF-C levels in recurrent papillary thyroid 
      carcinoma (PTC) patients. METHODS: Serum samples were collected preoperatively 
      from 85 patients with primary PTC, 44 with benign thyroid diseases, and 19 with 
      recurrent PTC. sVEGF and sVEGF-C levels were measured by enzyme-linked 
      immunosorbent assay. RESULTS: Twelve patients had locoregional recurrence only 
      while 7 patients had distant metastases, including 6 with concomitant or history 
      of locoregional recurrence. Patients with recurrent PTC had significantly higher 
      sVEGF (432 vs 263 pg/mL, P = .004) and sVEGF-C (6,433 vs 5,289 pg/mL, P = .006) 
      levels than benign controls. sVEGF level was significantly elevated in patients 
      with distant metastases compared with those of local recurrences only (580 vs 345 
      pg/mL, P = .037) while there was no significant difference of sVEGF-C level in 
      both subgroup of patients. sVEGF, but not VEGF-C, showed a linear correlation 
      with thyroglobulin levels in recurrent PTC patients. CONCLUSION: Both sVEGF and 
      sVEGF-C levels are elevated in patients with recurrent PTC, and sVEGF 
      distinguishes the presence of distant metastasis. Angiogenic markers should be 
      further evaluated for their clinical relevance in monitoring and predicting the 
      type of recurrence.
FAU - Yu, Xiao-Min
AU  - Yu XM
AD  - Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Lo, Chung-Yau
AU  - Lo CY
FAU - Lam, Alfred King-Yin
AU  - Lam AK
FAU - Lang, Brian Hung-Hin
AU  - Lang BH
FAU - Leung, Pauline
AU  - Leung P
FAU - Luk, John M
AU  - Luk JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Vascular Endothelial Growth Factor C)
SB  - IM
MH  - Adenocarcinoma, Papillary/*blood
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local/*blood
MH  - Thyroid Neoplasms/*blood
MH  - Vascular Endothelial Growth Factor A/*blood
MH  - Vascular Endothelial Growth Factor C/*blood
MH  - Young Adult
EDAT- 2008/12/02 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/12/02 09:00
PHST- 2008/03/10 00:00 [received]
PHST- 2008/07/03 00:00 [accepted]
PHST- 2008/12/02 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/12/02 09:00 [entrez]
AID - S0039-6060(08)00557-6 [pii]
AID - 10.1016/j.surg.2008.07.027 [doi]
PST - ppublish
SO  - Surgery. 2008 Dec;144(6):934-40; discussion 940-1. doi: 
      10.1016/j.surg.2008.07.027.